The Miami Stem Cell Therapy Podcast

miamistemcelltherapy

The Miami Stem Cell Podcast by STEMS Health Regenerative Medicine in Miami Beach, Florida, is an informational, synthetic narrated podcast designed to educate listeners about the science and practice of regenerative medicine. Each episode delivers clear, evidence-based insights on topics such as stem cell therapy, PRP, exosomes, peptides, and anti-aging innovations, reflecting the clinical expertise of Dr. Ankeet Choxi and Dr. Jarred Mait. Created for patients and wellness-minded listeners, the podcast simplifies complex medical topics while emphasizing safety, transparency, and real-world applications - helping you stay informed about the latest advances in regenerative and longevity medicine. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, (305) 677.0565.

Play

Open in

25 episodes
a few times a week
Avg 5 min
English

Episodes 25

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

#65
Thursday · 5 min
Ep 60 The Difference Between Authentic Dezawa MuseCells® and Look-Alike Products
As global interest in Muse cell science has grown, so has the number of products marketed using similar terminology. Understanding what actually separates authentic Dezawa MuseCells from look-alike products has become an increasingly important part of evaluating any claim in this space, whether the audience is a patient, a physician, or a researcher. The term Muse cell refers to a specific, scientifically defined subpopulation of stem cells, short for multilineage-differentiating stress-enduring cell, discovered by Professor Mari Dezawa at Tohoku University in 2010. As awareness of that discovery has spread, the term has sometimes been adopted by products with little or no connection to the original research or its licensed manufacturing pathway. This is not unusual when a genuinely novel discovery becomes widely known. Vocabulary tends to spread faster than rigor, and in cell-based medicine, where the products involved are introduced directly into the human body, that gap carries real consequences. Origin is the first place to look. Authentic Dezawa MuseCells are perinatal in origin, derived from donated umbilical cord tissue through a well-documented, ethically sourced process. Look-alike products may come from far less consistent or poorly disclosed sources, which affects both their biological properties and the ethical framework surrounding how they were obtained. Manufacturing is the second, and perhaps most decisive, factor. Authentic Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder for the Dezawa protocol. That includes documented chain of custody, sterility testing, and consistent identification through specific biological markers, SSEA-3 paired with CD105 for bone marrow-derived cells, or SSEA-3 paired with CD45 for cells sourced from peripheral blood. Products that cannot produce this kind of documentation cannot be verified as authentic, regardless of how confidently they are marketed. Validation is the third factor. Legitimate research has described properties such as non-tumorigenic pluripotency and a tissue-homing mechanism guided by the S1P-S1PR2 signaling pathway, findings that appear in peer-reviewed scientific literature connected to the original Dezawa protocol. Look-alike products often borrow this language, describing similar mechanisms, without being able to show that their specific product underwent comparable scientific validation. Put together, these three factors, origin, manufacturing, and validation, form a practical checklist. Is the product traceable to documented, ethically sourced tissue? Is it manufactured under verifiable GMP protocols with consistent marker identification? And is it connected to published research or documented clinical data, rather than general statements borrowed from someone else's science? Physicians incorporating Muse cell research into their practice, and patients evaluating treatment options, are both better served by insisting on clear answers to these questions rather than relying on branding or terminology alone. In a field still building its evidence base, that kind of scrutiny is what ultimately separates credible science from marketing.
#64
October 6 · 5 min
Ep 59 Stem Cell Tourism and Dezawa MuseCells®: How Patients Can Make Informed Decisions
Stem cell tourism describes the practice of traveling internationally to access regenerative medicine treatments that may be unavailable, restricted, or still in early research phases at home. As global interest in Muse cell science has grown, including in Dezawa MuseCells, so has the number of patients weighing whether to travel for access to this research. Understanding how to evaluate that decision matters as much as understanding the science itself. It helps to start with a clear distinction. Stem cell tourism is not inherently unsafe. Legitimate international clinics operate under credible manufacturing and clinical oversight standards, and for some patients, traveling abroad genuinely opens access to research unavailable elsewhere. The challenge is that the same global landscape enabling legitimate access also allows clinics with far less rigorous standards to market similar-sounding therapies without comparable safeguards. Published research on international stem cell tourism consistently points to one central recommendation: evaluate treatment options based on published clinical evidence, not testimonials or promotional claims. This is especially relevant for Muse cell science, where genuine research, involving properties such as non-tumorigenic pluripotency and a tissue-homing mechanism guided by the S1P-S1PR2 signaling pathway, exists alongside a marketplace where similar terminology is sometimes used loosely by clinics offering different or lower-quality products. Transparency is one of the most useful screening tools available to patients. A credible clinic should be willing to explain, in specific terms, how its cells are sourced and manufactured, and should be equally willing to discuss the current limitations of the evidence alongside any potential benefits. Authentic Dezawa MuseCells are manufactured under Good Manufacturing Practice protocols by MUSE Cell Innovations and identified using specific biological markers. A transparent clinic should confirm these details without hesitation. Language itself is worth watching closely. The term Muse cell has real scientific specificity, referring to a defined subpopulation identified by markers such as SSEA-3 combined with CD105 or CD45. In a global marketplace, however, similar language sometimes gets applied to products that have not undergone comparable research or manufacturing oversight. Patients can protect themselves by comparing how a clinic describes its product across different materials, a website, a consent form, and a direct conversation with staff. Inconsistencies between those sources are often a sign that marketing has moved faster than documentation. Finally, researchers increasingly recommend a practical test: ask whether the treating clinic is willing to communicate directly with a patient's physician at home, both before and after treatment. That willingness, or its absence, tends to say a great deal about whether a clinic is built around genuine clinical rigor or primarily around attracting patients. Combined with a focus on published evidence, transparent sourcing, and precise language, this kind of physician-to-physician dialogue gives patients a structured, evidence-based way to navigate a field that continues to expand rapidly around the world.
#63
October 2 · 4 min
Ep 58 What Patients Should Know Before Seeking Dezawa MuseCell® Therapy Abroad
Regulatory pathways for stem cell-based therapies vary widely from country to country, and that variation has led a growing number of patients to consider traveling abroad for access to Muse cell research, including Dezawa MuseCells. While international access can open doors that would otherwise be closed, it also places more responsibility on the patient to evaluate what they are actually being offered. The most important factor to assess is physician qualification. Patients should look for clear evidence of medical licensure, relevant specialty training, and specific experience with Muse cell protocols rather than general stem cell treatment. A credible physician will be able to speak to how many patients they have treated using a given protocol, what outcomes have been documented, and whether they participate in the broader professional community, including the conferences where manufacturing standards and clinical evidence are actively debated. Manufacturing verification matters just as much as physician credentials. Not every product marketed using similar terminology is manufactured to the same standard. Authentic Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder, and identified using specific biological markers, SSEA-3 combined with CD105 for bone marrow-derived cells, or SSEA-3 combined with CD45 for cells sourced from peripheral blood. Before booking any travel, patients should request documentation confirming these standards are actually being met. Continuity of care is one of the most commonly overlooked considerations. Because Muse cell research remains investigational, follow-up monitoring after treatment is essential, not optional. Patients should ask, before they travel, how a clinic plans to coordinate care once they return home. Will records be provided in a usable, translated format? Is there a clear point of contact if questions arise weeks or months later? Will a physician at home be willing to provide supportive care for someone who was treated elsewhere? There are also warning signs worth watching for. Clinics that guarantee specific outcomes, discourage second opinions, avoid detailed questions about manufacturing, or apply pressure toward a fast booking decision should prompt additional scrutiny. By contrast, clinics operating in good faith tend to welcome those same questions and provide documentation readily, because transparency is part of how credible regenerative medicine research is conducted. Taken together, these considerations point toward a simple approach: confirm that a clinic uses licensed, authentic protocols, verify the treating physician's relevant credentials and experience, request documentation of manufacturing and quality control standards, and clarify exactly how follow-up care will work before committing to travel. None of this removes the underlying uncertainty that comes with any investigational therapy, but it significantly reduces the risk of encountering a misrepresented or poorly regulated product, and it puts the patient in a stronger position to make a genuinely informed decision.
#62
September 30 · 5 min
Ep 57 Dezawa MuseCells® and the Future of Orthopedic Regenerative Care
Orthopedic medicine has long relied on a familiar progression: conservative treatment first, surgery when that fails. In recent years, a middle path has opened up in the form of biologic therapies, treatments designed to support the body's own repair processes before more invasive options become necessary. Increasingly, that conversation includes Muse cells, and specifically, Dezawa MuseCells. Muse cells were first identified in 2010 by Professor Mari Dezawa at Tohoku University. The name stands for multilineage-differentiating stress-enduring cells, a rare subpopulation found naturally in bone marrow, connective tissue, and peripheral blood. Two properties make them relevant to orthopedic research. First, they are pluripotent without being tumorigenic, meaning they can differentiate into multiple tissue types without the tumor-forming risk associated with some other pluripotent cells. Second, they exhibit what researchers describe as intelligent tissue homing, migrating toward sites of injury through a signaling pathway involving sphingosine-1-phosphate and a receptor called S1PR2. For joints, tendons, and connective tissue, this homing behavior has generated theoretical interest. Damaged musculoskeletal tissue often has limited blood supply, which slows natural healing. Researchers are studying whether cells capable of locating and responding to injury signals might have relevance in that context, alongside other orthobiologic approaches already in use, such as platelet-rich plasma and conventional mesenchymal stem cell therapies. Manufacturing plays a central role in how this research is evaluated. Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder for the Dezawa protocol. Cells are identified using specific markers, SSEA-3 paired with CD105 for bone marrow-derived cells, or SSEA-3 paired with CD45 for cells isolated from peripheral blood. That level of standardization matters because orthopedic tissue is highly variable, and consistency in what is being studied is essential to drawing reliable conclusions. Joint preservation, the broader clinical goal of delaying or avoiding joint replacement surgery, is where much of this research is aimed. Physicians exploring biologic strategies for musculoskeletal conditions are watching Muse cell research develop alongside other established approaches, with an emphasis on building outcome data rather than making early promises. Current applications remain investigational, and researchers are careful to frame ongoing work as part of a longer evidence-building process rather than a finished clinical solution. Looking ahead, the future of Muse cell research in orthopedics will likely depend on the same factors driving progress across regenerative medicine broadly: standardized protocols, transparent outcome tracking, and rigorous comparison against existing treatments. As that evidence base grows, musculoskeletal medicine may increasingly incorporate findings from this research, provided that manufacturing authenticity and clinical documentation remain the foundation of how the field moves forward.
#61
September 28 · 5 min
Ep 56 The Growing Interest in Dezawa MuseCells® at Medical Conferences Worldwide
Regenerative medicine conferences around the world have a new fixture on their agendas: Muse cells, and specifically, Dezawa MuseCells. Named for the researcher who discovered them, Professor Mari Dezawa of Tohoku University, these cells were first identified in 2010 as a rare subpopulation of stem cells found naturally in bone marrow, connective tissue, and peripheral blood. Since then, interest has moved from laboratories into conference halls, where physicians now gather to discuss what these cells are, how they are manufactured, and what the science actually supports. Four themes tend to dominate these sessions. The first is manufacturing quality. Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder for the Dezawa protocol. The cells are perinatal in origin, meaning they are derived from donated umbilical cord tissue, and they are identified using specific biological markers. Cells isolated from bone marrow are confirmed using SSEA-3 alongside CD105, while those isolated from peripheral blood are confirmed using SSEA-3 alongside CD45. For physicians, this level of specificity is not a technical footnote. It is the foundation of trust in any biologic product. The second theme is patient selection. Because Muse cells behave differently than conventional mesenchymal stem cells, physicians spend considerable conference time discussing which patients might be appropriate candidates for investigational approaches, what diagnostic steps should come first, and how outcomes should be tracked and documented. Part of what makes this conversation necessary is the unusual biology involved. Muse cells are pluripotent, meaning they can differentiate into cell types from all three embryonic germ layers, yet research has shown they do not form tumors, a property that sets them apart from many other stem cell types under investigation. That leads to a mechanism researchers frequently highlight: tissue homing. When introduced into the body, Muse cells appear to migrate on their own toward sites of injury, guided by a signaling pathway involving a molecule called sphingosine-1-phosphate, produced by damaged tissue, and a receptor known as S1PR2. This intelligent homing behavior is one of the most discussed findings in current Muse cell research, and it continues to generate scientific curiosity about how the cells might support the body's own repair processes. The third theme is evidence development. Regenerative medicine as a field is still building the body of clinical data needed to move promising science into widely accepted practice. Conference tracks increasingly cover clinical-grade products such as CL2020, along with updates on research into conditions like stroke, myocardial infarction, and acute respiratory distress syndrome. Physicians attending these sessions are encouraged to view current findings as part of an ongoing research trajectory rather than a finished conclusion. Finally, conferences look ahead. Discussions increasingly touch on where this research may lead, including orthopedic applications involving joints and connective tissue, and broader systemic approaches to tissue support. Across every session, one message remains constant. Protocol authenticity and physician education are what separate credible regenerative medicine research from unsubstantiated claims. As global interest in Muse cells continues to grow, medical conferences remain the place where that distinction is made clearest.
#60
August 18 · 5 min
Ep 55 Why More Physicians Are Learning About Dezawa MuseCells®
Today’s episode is a little different. Instead of focusing on the science itself, we’re looking at a trend among the physicians who study it: a growing number of regenerative medicine specialists are actively seeking out structured education on Muse cells. Why now? A few things seem to be driving it. First, the published research base has simply grown. Since Professor Mari Dezawa and colleagues first characterized Muse cells in 2010, the volume of peer-reviewed literature covering their biology, their mechanism, and early clinical trial data has expanded steadily across specialties including cardiology, neurology, and dermatology. That gives physicians an actual body of evidence to study, rather than relying on marketing claims or anecdotal reports. Second, patient interest is rising. As public awareness of regenerative medicine grows, physicians report fielding more direct questions from patients about biologic therapies, Muse cell-based approaches included. That creates real demand for physicians to be able to explain, accurately, what is and isn’t established about a given therapy. Third, and this one is important: terminology in this space isn’t always tightly regulated. Products described using similar language can differ substantially in origin, manufacturing standard, and scientific validation. So part of physician education now involves learning to distinguish an authentic, well-documented protocol from a similarly named product that may not have the same evidence behind it. So what does this education actually look like in practice? A lot of it happens at regenerative medicine conferences, which give physicians direct access to researchers presenting original data and a chance to ask detailed technical questions. Beyond that, many physicians build an ongoing habit of tracking peer-reviewed literature as it’s published, across the relevant specialty journals, rather than treating a single training session as sufficient. And increasingly, physician education includes direct review of a specific manufacturer’s protocol documentation: how the cells are sourced, isolated, validated, and quality-tested before clinical use. That last point connects to a theme that comes up again and again in this space: standardization. Consistent isolation methods, validated potency and purity testing, and reproducible manufacturing processes matter because published research is generated using specific, validated protocols. A product using similar terminology but a different or unvalidated protocol may not produce comparable results, even if it sounds the same on paper. Ultimately, this translates into better patient conversations. Physicians who’ve done the work of reviewing the underlying literature are better positioned to set accurate expectations, explaining clearly which applications remain investigational, which trial phases have been reached, and what a given patient should realistically expect. Groups like STEMS Health, a regenerative medicine practice in Miami Beach, Florida, reflect this broader trend, prioritizing ongoing education grounded in peer-reviewed research and manufacturing transparency. As with every episode, this content is for general educational purposes only and isn’t medical advice. Any regenerative medicine procedures mentioned may be considered investigational or not FDA approved for certain conditions, so speak with a licensed healthcare provider about what’s appropriate for you. That wraps up today’s episode. Thanks for listening.
#59
August 14 · 5 min
Ep 54 The Science of Tissue Homing: How Dezawa MuseCells® Respond to Injury
If you’ve listened to this podcast before, you’ve probably heard us mention a property called tissue homing. Today, let’s actually unpack what that means and how it works. In cell-based research, homing refers to the ability of cells, once administered, to migrate toward a specific site in the body rather than distributing randomly or getting stuck somewhere unrelated to the injury. That distinction matters more than it might sound. Standard mesenchymal stem cells, for instance, are known to become passively trapped in the lungs after intravenous injection, regardless of where the actual injury is. A cell type capable of active, targeted homing offers a more direct path to the treatment site, without needing surgical delivery. Muse cells, identified by Professor Mari Dezawa and colleagues, are the property most consistently discussed in this context. Here’s the mechanism: when tissue is damaged, anywhere in the body, it releases a lipid signaling molecule called sphingosine-1-phosphate, or S1P. Researchers describe it as a kind of universal distress signal, with local levels rising at the site of damage, whether that damage comes from a heart attack, a spinal cord injury, or radiation exposure. Muse cells express a specific receptor for that signal, called S1PR2, which allows circulating cells to detect elevated S1P and travel toward it. In several animal studies, differentiated cells that arrive this way have gone on to integrate into existing tissue structures, including neuronal circuits studied in spinal cord and brain research. This matters to researchers for a couple of practical reasons. Because the S1P signal is released by damaged tissue generally, rather than being specific to one organ, the homing mechanism has been studied across cardiac, neurologic, dermatologic, and gastrointestinal research, all building on the same underlying biology rather than starting from separate premises each time. And because some injury sites are diffuse, hard to access, or simply not good candidates for direct injection, a cell type that can be delivered intravenously and still find its way to the target offers a practical advantage. So how do scientists actually verify this happens? In the lab, researchers typically label Muse cells with fluorescent or luminescent markers before administering them, then track their location over time to confirm whether, and how much, they accumulate at the injury site rather than elsewhere. Some studies have gone further, using receptor-blocking agents to show that when the S1PR2 pathway is inhibited, homing and the associated tissue repair drop off significantly, which is fairly strong evidence for how central that mechanism actually is. A couple of caveats are worth mentioning. Not every infused Muse cell reaches the injury site. Published research indicates only a portion do, with the rest distributed elsewhere or cleared through normal processes. And this homing behavior does appear to be a distinguishing feature of Muse cells specifically. Standard mesenchymal stem cells that lack the SSEA-3 marker have shown less effective homing through this same pathway in research studies. STEMS Health, a regenerative medicine practice based in Miami Beach, Florida, follows this line of research as part of tracking how the science develops. As always, this is general educational content, not medical advice, and related procedures may be investigational or not yet FDA approved. Consult a licensed healthcare provider for guidance specific to you. Thanks for listening, and we’ll see you in the next episode.
#58
August 12 · 5 min
Ep 53 How Dezawa MuseCells® May Shape the Future of Regenerative Medicine
Today we’re zooming out a bit to talk about where regenerative medicine as a field seems to be headed, and why one particular cell type, the Muse cell, keeps coming up in that conversation. Over the past decade, regenerative medicine research has been moving away from one-size-fits-all protocols and toward approaches that account for differences between patients: the type of injury, the stage of disease, and individual biology. That shift has been driven partly by better diagnostic imaging and biomarker tools, which let researchers get a clearer picture of who might respond to a given treatment, and when. Cell-based therapies sit right in the middle of that trend, but their usefulness depends heavily on whether a given cell type can actually be delivered precisely and consistently. This is where Muse cells, first identified by Professor Mari Dezawa, draw particular interest. Because they can detect an injury signal called sphingosine-1-phosphate through a receptor called S1PR2, they’re able to be given intravenously and still concentrate at a site of tissue damage, whether that’s the heart, the spinal cord, or the skin. That’s a meaningful difference from therapies that require direct injection or surgical placement at a specific location. Still, there are real open questions researchers are working through before this potential becomes an established clinical reality. How many cells are actually needed for a given condition, and does repeated dosing outperform a single administration? How long do differentiated cells persist in the body, and is any reparative effect sustained over years rather than months? Do promising early results in one condition, like heart attack recovery, generalize to other organ systems? Can manufacturing of a frozen cell product scale up to meet demand across multiple treatment centers? And how will regulators evaluate a therapy with such a broad range of potential applications? Researchers also tend to frame this work as part of a bigger-picture shift toward personalized regenerative medicine, one where diagnostics help determine which patients are likely to benefit from a given intervention, and where protocols developed in one specialty, say cardiology, inform work happening in neurology, orthopedics, or dermatology. It’s a similar logic to what’s already played out in precision oncology, where biomarker-driven treatment selection has become standard practice. It’s worth being direct about the current state of things, though. Personalization in this context mostly describes a research direction, not an established, individualized treatment model. Most published clinical trials still use standardized dosing for a given condition. And there’s no evidence yet that Muse cells require the kind of donor matching used in organ transplants, though that’s an area of continued study rather than settled practice. Groups like STEMS Health, a regenerative medicine practice in Miami Beach, Florida, follow this research as part of understanding where the field may be going next. As always, this is general information, not medical advice, and any regenerative procedures discussed may be investigational or not yet FDA approved for certain conditions. Thanks for listening, and we’ll catch you next time.
#57
August 10 · 4 min
Ep 52 What Makes Dezawa MuseCells® Unique Without Genetic Modification?
Let’s talk today about a distinction that comes up often in stem cell research: the difference between cells that are engineered to become pluripotent, and cells that are simply found that way in the body already. Most of the attention-grabbing stem cell science over the past two decades has centered on induced pluripotent stem cells, or iPSCs, first developed by Shinya Yamanaka. Making an iPSC involves taking an adult cell and introducing specific transcription factors to push it back into an embryonic-like state. It’s a clever workaround for the ethical and supply issues tied to embryonic stem cells, but it introduces its own technical challenges, including the risk that if any of those reprogrammed cells remain undifferentiated after transplant, they can form a type of tumor called a teratoma. Embryonic stem cells carry similar tumorigenicity concerns of their own. Muse cells take a different path entirely. They were first identified in 2010 by Professor Mari Dezawa and colleagues, and they occur naturally in adult tissue, including bone marrow, fat tissue, and peripheral blood. Researchers identify them using a surface marker called SSEA-3, and because they already exist in the body in this state, isolating them is a matter of sorting cells that are already there, rather than reprogramming or engineering anything. No viral vectors, no transcription factor reprogramming, no embryonic tissue involved. That distinction turns out to matter for a few practical reasons researchers care about. First, tumorigenicity: published animal studies to date haven’t shown Muse cells forming teratomas, in contrast to the documented risk associated with iPSCs and embryonic stem cells. Second, manufacturing complexity: because there’s no reprogramming or differentiation-induction step required, the production process is simpler than what’s needed for engineered pluripotent cells. Third, immune compatibility: Muse cells express a marker called HLA-G, which is associated with immune tolerance, similar to mechanisms seen in placental tissue. Researchers have studied whether that property might reduce the need for donor matching or immunosuppressive drugs in certain contexts. And fourth, there’s the homing behavior we’ve covered on this show before, the ability of Muse cells to travel to an injury site through a signaling pathway involving sphingosine-1-phosphate and a receptor called S1PR2, a property not shared by standard mesenchymal stem cells to the same degree. Put together, natural origin, an apparent absence of tumor formation in current studies, and built-in injury homing make Muse cells a distinct subject of study compared to both conventional mesenchymal stem cells and engineered pluripotent cell types. That’s part of why groups like STEMS Health, a Miami Beach-based regenerative medicine practice, keep a close eye on this area of the literature. Thanks for tuning in, and we’ll see you next time.
#56
August 8 · 4 min
Ep 51 Why Researchers Continue Studying Dezawa MuseCells® Across Multiple Medical Fields
Welcome back to the show. Today we’re taking a closer look at a naturally occurring stem cell that keeps showing up in research papers across a surprising range of medical specialties: the Muse cell, discovered in 2010 by Professor Mari Dezawa and her colleagues at Tohoku University. What makes this cell type so interesting to scientists isn’t just that it’s pluripotent-like, meaning it has the potential to become many different cell types. It’s that Muse cells appear to know where to go. They carry a receptor called S1PR2, which detects a signaling molecule released by damaged tissue, called sphingosine-1-phosphate. When tissue anywhere in the body is injured, Muse cells circulating in the blood can sense that signal and travel toward it. That mechanism isn’t specific to any one organ, which helps explain why researchers in neurology, cardiology, orthopedics, pulmonology, and dermatology have each, independently, started investigating the same cell type. In neurology, scientists have looked at how Muse cells behave after stroke and spinal cord injury. In cardiology, researchers have studied whether these cells home to heart tissue after a heart attack, and whether they can differentiate into the kinds of cells that make up heart muscle and blood vessels. Some of that cardiology work has moved into early-phase human trials, largely in Japan, alongside similar early trials for conditions like ALS, spinal cord injury, and a genetic skin condition called epidermolysis bullosa. Orthopedic and pulmonary research remains earlier stage, still largely limited to laboratory and animal studies. It’s worth pausing here to be clear about what all of this does and doesn’t mean. Early-phase clinical trials are designed to answer questions about safety and dosing. They are not the same as full regulatory approval, and no Muse cell-based product currently holds that kind of approval for routine use in the United States. Anything you hear described in the research literature should be understood as investigational unless a specific regulatory clearance is cited. So why does it matter that so many different fields are studying the same cell independently? Because when neurologists, cardiologists, and dermatologists are all seeing similar patterns, it strengthens the overall case for the underlying biological mechanism, even while each specialty is still working through its own condition-specific questions. Researchers tend to track a similar set of themes across this work: how precisely the cells home to an injury site, whether they reliably turn into the right kind of tissue once they arrive, how dosing and repeat administration affect outcomes, and what the long-term safety picture looks like. Organizations like STEMS Health, a regenerative medicine practice based in Miami Beach, Florida, follow this research closely as part of staying current on where the science stands. If you’re curious about Muse cell research, it’s a field worth watching, and one that’s likely to keep generating new questions for years to come. That’s it for today’s episode. Thanks for listening.
#55
August 5 · 4 min
Ep. 50: How Dezawa MuseCells® Became a Global Conversation in Regenerative Medicine
How Dezawa MuseCells Became a Global Conversation in Regenerative Medicine Drs. Ankeet Choxi and Jarred Mait at STEMS Health often get a version of this question from patients who are new to regenerative medicine. If Muse cells are such a big deal, why did it take this long for me to hear about them? The answer is actually a pretty good sign, because it shows this technology grew the slow, credible way, not through a marketing push. It started in two thousand ten, when Professor Mari Dezawa's team published the original discovery in the Proceedings of the National Academy of Sciences, one of the most respected scientific journals in the world. That single publication led to more research, including additional papers and a detailed methodology paper in twenty thirteen that let other labs reproduce her work. Over time, Dezawa herself authored more than two hundred peer reviewed papers, and her research earned real institutional recognition, including Japan's Commendation for Science and Technology and a fellowship in the U.S. National Academy of Inventors. From there, the science expanded well beyond its original context. Researchers began studying Muse cells in neurology, cardiovascular medicine, orthopedics, and pulmonary conditions, moving through preclinical work and into Phase two human trials in Japan. That kind of cross disciplinary interest does not happen with a discovery that does not hold up under scrutiny. It happens when independent research groups keep finding something worth studying. Physician education followed a similar path. Conferences and continuing education programs gave doctors a chance to engage directly with the underlying research, ask questions about manufacturing and patient selection, and bring that understanding back into their own practices. That is a very different growth pattern than a product that spreads through advertising alone. Only in the last few years has patient awareness really caught up to the research. And that creates a new challenge. As more people search for information about Muse cells, more products and clinics have started using similar language, which makes it more important than ever to understand where a given treatment actually comes from. Drs. Choxi and Mait see this as a good problem to have. More awareness means more patients asking better questions, and more clinics being held to a higher standard when they talk about this technology. The story is still being written too, since research keeps expanding into new conditions and new applications every year. If you want to understand how more than a decade of research applies to your own situation, reach out to STEMS Health and start a real conversation with our team.
#54
August 3 · 4 min
Ep. 49: Why Authentic Dezawa MuseCells® Matter More Than Ever
Why Authentic Dezawa MuseCells Matter More Than Ever This is one of the most important conversations Doctors Ankeet Choxi and Jarred Mait have with patients at STEMS Health, because it is also one of the most misunderstood. As Muse cells have become more well known, the number of products and clinics using that name has grown right along with it. And here is the uncomfortable truth. Using the name does not automatically mean a product is the real thing. Authentic Dezawa MuseCells refers specifically to cells isolated and manufactured according to Professor Mari Dezawa's validated protocols, using defined markers and culture conditions that have actually been published and peer reviewed. That is a scientific standard, not a marketing label. A product can call itself a Muse cell and still be produced through a completely different process, with different sourcing, different quality control, and none of the same published research behind it. This matters because the traits that make Muse cells valuable in the first place, their stress tolerance, their broader differentiation ability, their tendency to migrate toward damaged tissue, and their strong safety profile, are specific to cells isolated through that validated process. If a product skips that process, there is no scientific basis for assuming it shares those same characteristics, no matter how similar the marketing sounds. So what should you actually do with this information? Ask direct questions before committing to any treatment. Is this based on Dezawa's specific validated protocol? What is the manufacturing source, and what quality control standards govern it? What does the actual published research say about this exact product, not just the cell type in general? A provider who knows the answers, and is willing to share them, is telling you something important. So is a provider who cannot. This is also where physician expertise comes in. A physician who understands the underlying research is far better equipped to set realistic expectations and match you with the right treatment, rather than presenting early stage research as a guaranteed result. That is exactly the kind of conversation Drs. Choxi and Mait aim to have with every patient who walks through the door. As this field continues to grow, that gap between authentic, validated products and everything else using similar language is not going away on its own. If anything, growing patient interest tends to increase the incentive for products to borrow recognizable scientific language, whether or not the manufacturing behind them actually earns it. That is not a reason to be discouraged, it is just a reason to ask better questions before you commit to anything. If you want a straight answer about what you are actually being offered, reach out to STEMS Health and talk with our team.
#53
July 31 · 4 min
Ep. 48: Understanding the Dezawa Protocol: Why Standardization Matters
Understanding the Dezawa Protocol: Why Standardization Matters Patients at STEMS Health often ask Drs. Ankeet Choxi and Jarred Mait a version of the same question. If Muse cells are so rare, how does anyone actually isolate them consistently? The answer comes down to something called the Dezawa Protocol, and it is a bigger deal than most people realize. The Dezawa Protocol is the validated laboratory methodology developed by Professor Mari Dezawa's team for identifying and isolating Muse cells from a broader population of mesenchymal stem cells. It is not a product. It is a process, and that distinction matters enormously in medicine. A discovery is only as useful in the clinic as the method used to reproduce it reliably, batch after batch, lab after lab. Here is why that is such a challenge in the first place. Muse cells make up a small percentage of any given stem cell culture. You cannot just look at cells under a microscope and pick out the right ones. The protocol solves this by relying on specific, defined markers, most notably something called SSEA three, a marker linked to pluripotent like cells. It also specifies the exact culture conditions needed to preserve the cells' natural stress tolerant characteristics through processing. Without that level of specificity, one lab's version of a Muse cell could end up meaningfully different from another lab's version, even if both used the same name. This is also where things shift from a research protocol into a manufacturing standard. Producing cells for actual clinical use means adding sterility standards, documentation, and quality control checkpoints at every stage, well beyond what is needed to publish an academic paper. That layer of oversight is what allows a manufactured product to stay tied to the same research base it claims to represent, rather than drifting into something else entirely over time. This is exactly why Doctors Choxi and Mait encourage patients to ask specific questions before choosing a treatment. Is this based on Dezawa's actual validated protocol, or something using similar language without the same process behind it? What quality control measures are actually in place? These are not rhetorical questions. The answers tell you whether a treatment is grounded in reproducible science, or just borrowing familiar terminology. Manufacturing consistency will not answer every question about whether a treatment is right for you, but it is one of the clearest signals of scientific credibility available. Protocols like this one are not necessarily fixed forever either. As research continues, methodologies are sometimes refined to address new questions about long term consistency and stability, which is a normal part of how any area of regenerative medicine matures over time. If you want to understand exactly how this applies to a treatment you are considering, reach out to STEMS Health and talk with our team directly.
#52
July 29 · 4 min
Ep. 47: Why Dezawa MuseCells® Are Different: Understanding the Science
Why Dezawa MuseCells Are Different: Understanding the Science At STEMS Health, Drs. Ankeet Choxi and Jarred Mait get asked this question in almost every consultation. Aren't Muse cells just mesenchymal stem cells with a different name? The short answer is no, and the difference actually matters quite a bit. Mesenchymal stem cells, or MSCs, are one of the most widely used cell types in regenerative medicine. They come from places like bone marrow and fat tissue, and they mostly work through signaling, calming inflammation and encouraging the surrounding tissue to repair itself. For a long time, researchers treated a batch of MSCs as one uniform population. But Professor Mari Dezawa's research showed that is not quite accurate. Hidden inside those MSC cultures is a smaller subpopulation of cells that behave very differently, and that subpopulation is what we now call Muse cells. The first thing that sets them apart is stress tolerance. In the lab, Muse cells can survive conditions that would normally kill a cultured cell, things like oxygen deprivation, harsh enzymatic processing, and extended nutrient starvation. That resilience is part of what makes them consistent to work with during manufacturing. The second big difference is differentiation capacity. Standard MSCs generally turn into a narrower set of cell types, mostly bone, cartilage, and fat. Muse cells have been shown in published research to differentiate into cell types representing all three embryonic germ layers, a trait usually associated with pluripotent stem cells. And unlike embryonic stem cells or induced pluripotent stem cells, Muse cells occur naturally in the body and do not require genetic reprogramming, which is part of why published research has not shown the tumor risk associated with some other pluripotent cell types. Then there is tissue homing. This is one of the more remarkable behaviors described in the literature. When introduced into the body, Muse cells appear to migrate toward damaged tissue on their own, responding to signals released by the injury itself, rather than distributing randomly. Researchers are still studying exactly how significant this is for different conditions, but it is one of the main reasons this cell type continues to draw so much scientific attention. None of this means every product labeled as a Muse cell is the same. Isolating this specific subpopulation requires a validated process, and not every manufacturer follows it. That is exactly why Drs. Choxi and Mait spend time walking patients through where their specific product actually comes from, rather than relying on a name alone. If you want to understand how these differences apply to your own treatment options, reach out to STEMS Health and set up a real conversation with our team.
#51
July 28 · 4 min
Ep. 46: Who Is Professor Mari Dezawa? The Scientist Behind Dezawa MuseCells®
Who Is Professor Mari Dezawa? The Scientist Behind Dezawa MuseCells If you have spent any time researching regenerative medicine, you have probably come across the name Mari Dezawa. At STEMS Health, Drs. Ankeet Choxi and Jarred Mait hear the same question all the time. Who is this person, and why does her name show up on so much of the research behind Muse cells? Professor Dezawa is a physician and neuroscientist based at Tohoku University in Japan. She did not start out as a stem cell researcher. She trained in clinical medicine, then spent years studying neural regeneration before her work eventually led her into cell biology. That path matters, because it means the science behind Muse cells was built by someone who spent years in clinical practice first, not someone who jumped straight into a lab with a theory to prove. The discovery itself came out of an unexpected observation. In two thousand three, a member of her lab was working with cultured bone marrow stem cells and noticed a small group of cells behaving differently than the rest. Instead of dismissing it, Dezawa and her team investigated further. That investigation eventually led to identifying a distinct subpopulation of cells that could survive conditions that would normally destroy a cultured cell, and that showed the ability to differentiate into multiple cell types. She named them Muse cells, short for multi lineage differentiating stress enduring cells, and published the discovery in the Proceedings of the National Academy of Sciences in twenty ten. Since then, her research has continued to expand. She has authored more than two hundred peer reviewed papers, and her work has been recognized with honors including Japan's Commendation for Science and Technology and a fellowship in the U.S. National Academy of Inventors. Her lab also published a detailed methodology paper in twenty thirteen, laying out exactly how Muse cells should be isolated and identified, so that other researchers around the world could reproduce the findings consistently. Why does any of this matter if you are a patient, not a scientist? Because the strength of a regenerative therapy comes down to the strength of the science behind it. Knowing that Muse cells were identified through careful, peer reviewed research, by a physician with decades of clinical background, gives you a much clearer picture of what you are actually being offered when a clinic mentions this technology. At STEMS Health, Drs. Choxi and Mait often walk patients through exactly this kind of background before ever discussing treatment options, because understanding where a therapy comes from is part of understanding whether it is right for you. If you want to know more about how Professor Dezawa's research applies to your specific situation, the next step is a real conversation with our team, not just a podcast. Reach out to STEMS Health to learn more.
#48
July 8 · 6 min
Ep. 45 What Should Happen After a Dezawa Muse Stem Cell Injection?
What Should Happen After a Dezawa Muse Stem Cell Injection? Most of the attention in regenerative medicine falls on the treatment itself. The decision to pursue therapy. The consultation. The injection. And then, for many patients, a period of uncertainty — because no one has clearly explained what comes next. At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait treat that post-procedure period as a clinical phase in its own right. What happens in the weeks and months following a Dezawa Muse stem cell injection is not a passive waiting period. It is an active phase of biological activity — one that is shaped by patient behavior, clinical oversight, and the structure of follow-up care. Understanding the timeline begins with a foundational concept: the injection is the beginning of the regenerative process, not its conclusion. In the first week after a Muse cell injection, the biological focus is on the early tissue response. Some mild soreness, local swelling, or increased awareness of the injection area is normal and expected. It reflects the body's response to both the procedural intervention and the cellular activity beginning at the target site. This is not a sign that something has gone wrong. In most cases, it is a sign that the tissue is responding. During this window, certain medications warrant particular attention. Systemic corticosteroids and specific anti-inflammatory agents can blunt the early regenerative response — the same response that Muse cell therapy is designed to initiate. At STEMS Health, patients receive specific guidance on which medications to avoid and for how long. They are also given clear parameters for what warrants a call to the practice: significant or worsening swelling beyond 72 hours, fever or systemic symptoms, new neurological findings, or any change that falls outside the expected pattern. Weeks two through six represent what clinicians at STEMS Health describe as the early regenerative window. During this period, cell homing and early differentiation are most active. Many patients begin noticing incremental shifts — changes in pain levels, modest improvements in mobility or function, or simply a sense that something in the treated area is different. The progression is rarely linear. Some patients experience a temporary increase in awareness of the treatment area before improvement becomes consistent. That pattern is recognized and expected. A structured clinical check-in during this window is not optional in the STEMS Health model. It is a deliberate assessment — an opportunity for the treating physicians to evaluate whether the response is tracking appropriately and whether any modification to the patient's activity protocol or rehabilitation guidance is warranted. For most musculo-skeletal conditions, the primary improvement arc unfolds between weeks six and sixteen. This is the period when tissue remodeling and structural repair — stimulated by Muse cell activity — become measurable through both patient-reported outcomes and clinical examination. Patients who have followed activity guidance, maintained appropriate anti-inflammatory management, and stayed engaged with follow-up appointments during this window consistently demonstrate better outcomes than those who have not. Engagement during the regenerative window is not incidental to the result. It is part of the treatment. For neurological conditions, complex degenerative presentations, or patients who received combination protocols, the relevant timeline extends further. Neurological regeneration is a slow, staged biological process. Progress may not be dramatic in the early months, and the absence of dramatic change should not be interpreted as treatment failure. At STEMS Health, longer-term follow-up is structured around the specific condition and clinical trajectory of each patient. Every patient treated at STEMS Health receives a post-procedure care plan before leaving the practice. It is not a general handout. It is a personalized document built around the patient's specific condition, the procedure that was performed, and the recovery timeline appropriate to their clinical profile. Follow-up appointments are scheduled, not left to the patient to initiate. The physicians remain accessible between appointments for questions or concerns that arise outside the scheduled intervals. Patients evaluating regenerative medicine providers should ask explicitly what the post-procedure protocol includes — how often they will be seen, what is being monitored, and how the practice responds if progress deviates from expected benchmarks. A provider whose post-procedure care is clearly defined and clinically structured is a provider whose commitment to the outcome extends beyond the procedure itself. The regenerative process requires time, appropriate clinical conditions, and physician oversight that does not end when the needle is withdrawn. At STEMS Health, that oversight is designed into the treatment model — because the outcome of a Muse cell injection is shaped as much by what follows as by the injection itself.
#50
July 7 · 5 min
Ep 44 How to Identify Authentic Dezawa MuseCells®: Why Verification Matters More Than Ever
To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- How to Know if Your Dezawa MuseCells® Are Authentic As regenerative medicine continues to advance, more patients are hearing about Dezawa MuseCells® and their unique biological properties. At the same time, the growing popularity of this technology has created an important challenge: products being marketed as "MUSE cells" that are not authentic Dezawa MuseCells®. In today's episode, we'll explain why authenticity matters, what questions patients should ask, and why scientific validation is more important than ever. When an innovative medical technology gains attention, it's common for similar products to enter the marketplace. Regenerative medicine is no exception. As awareness of Dezawa MuseCells® has increased, so has the number of products using the term "MUSE." However, the name alone does not guarantee authenticity. According to scientists involved with the development and study of the technology, if a product was not generated using Professor Mari Dezawa's validated derivation and characterization protocols, it should not be considered an authentic Dezawa MuseCell®. That distinction isn't about marketing. It's about scientific validation. Authentic Dezawa MuseCells® have been investigated through decades of laboratory research, preclinical studies, and clinical experience. Their biological characteristics have been documented using validated manufacturing methods and rigorous quality standards. One of the most remarkable characteristics described in the scientific literature is their ability to naturally home to damaged tissue. Unlike many other cellular products, authentic Dezawa MuseCells® respond to signals released by injured tissue and migrate to those locations without external guidance. This unique biological behavior is one of the reasons they continue to generate significant interest within the field of regenerative medicine. However, these characteristics cannot simply be assumed because another product carries a similar name. The defining properties associated with authentic Dezawa MuseCells® result from specific derivation, characterization, validation, and manufacturing processes. Without those validated methods, there is no scientific basis to conclude that another product possesses the same biological profile or safety characteristics. This is why patients should never hesitate to ask questions before receiving any regenerative medicine treatment. Ask whether the product being used is an authentic Dezawa MuseCell®. Ask whether it was generated using Professor Mari Dezawa's validated protocol. Ask whether the manufacturer can document the product's origin and quality standards. And ask what published scientific evidence supports the specific cellular product being offered. These are reasonable questions, and reputable providers should welcome them. Another important development is that patients no longer need to travel internationally to access authentic Dezawa MuseCells®. They are now available in the United States through MuseCell® Innovations licensed manufacturers, providing physicians with access to products produced under validated manufacturing standards. As interest in regenerative medicine continues to grow, education remains one of the most valuable tools patients have. Similar names do not necessarily represent similar science. A logo can be copied. A product name can be copied. Scientific validation cannot. Understanding that distinction can help patients make more informed decisions and have more meaningful conversations with their healthcare providers. Thank you for listening to The Miami Stem Cell Podcast, presented by STEMS Health. To learn more about regenerative medicine and authentic Dezawa MuseCells®, visit STEMS Health for additional educational resources. This podcast is provided for informational and educational purposes only and should not be considered medical advice. Individual treatment decisions should always be made in consultation with a qualified healthcare professional.
#47
July 6 · 6 min
ep 43 What Actually Determines Success in Dezawa Muse Stem Cell Therapy?
To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- What Actually Determines Success in Dezawa Muse Stem Cell Therapy? There is a gap in how regenerative medicine is often evaluated — by patients, by the industry, and sometimes by providers themselves. The conversation centers on what can be measured at the lab level: cell counts, processing standards, product certifications. These are visible. They are quantifiable. They are easy to compare. They are also, by themselves, remarkably poor predictors of whether a patient actually improves. At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait have identified three factors that consistently differentiate patients who achieve meaningful outcomes from those who do not. None of them are lab metrics. All of them are clinical. The first is diagnostic precision. Dezawa Muse stem cells are not a broad-spectrum treatment for pain or degeneration. They are a targeted biological intervention with specific mechanisms — stress-guided homing, tissue-specific differentiation, immunomodulation. That targeting only works when the tissue being treated is correctly identified. A patient presenting with knee pain might have osteoarthritis, meniscal pathology, periarticular bursitis, or some combination. These are different conditions with different structural implications. Treating the wrong pathology — or treating the right pathology with an imprecise understanding of its extent — produces results that fall short of what the therapy is capable of. At STEMS Health, every protocol begins with a confirmed diagnosis. Imaging. Clinical correlation. Laboratory workup. The protocol is designed around that diagnosis — not around a symptom description or a generalized complaint. The second factor is injection technique. Even a well-characterized, high-potency Muse cell preparation achieves very little if it is not delivered accurately to the target tissue. Injection technique is a procedural skill that encompasses approach angle, imaging guidance, depth calibration, and the prevention of cellular leakage into non-target tissue. At STEMS Health, musculo-skeletal injections are performed under ultrasound guidance — real-time visualization that confirms the cells are deposited precisely at the intended site, whether that is within a joint capsule, a tendon sheath, a disc space, or a neural structure. That precision is not incidental to the therapy. It is the mechanism by which the cells reach the tissue that needs them. Without it, even a superior preparation becomes a clinical approximation. The third factor is post-procedure follow-up care. The injection is not the conclusion of treatment. It is the beginning of a biological process that unfolds over days, weeks, and months. Muse cells initiate cellular homing, differentiation, and tissue remodeling across an extended regenerative window. The clinical environment during that window directly influences how well those processes develop. Patients who receive an injection and then disengage from structured care consistently underperform compared to patients who remain engaged. At STEMS Health, follow-up is not a courtesy — it is a clinical protocol. Scheduled reassessments allow the treating physicians to monitor functional progress, adjust rehabilitation guidance, manage the anti-inflammatory environment appropriately, and identify early signals that warrant attention. Imaging follow-up is conducted when indicated to assess structural changes at the treatment site. Taken together, these three factors tell a consistent story. The lab produces the tool. The physician determines whether that tool reaches its target, in the right patient, with the right diagnosis, delivered with precision, and supported through the recovery window with clinical intent. When evaluating a regenerative medicine provider, patients are best served by asking not about lab credentials — but about the diagnostic process, the injection guidance protocol, and the structure of follow-up care. Those answers will reveal far more about the likely outcome than any comparison of cell counts or facility certifications. At STEMS Health, the sequence is consistent across every patient: diagnose with precision, design the protocol around that diagnosis, deliver with imaging guidance, and follow up with clinical purpose. That sequence is not a differentiator. It is the standard.
#49
July 3 · 4 min
Ep 42 MSCs vs. Dezawa MUSEcells™: Understanding Dose, Value, and When Each Makes Sense
To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- MSCs vs. Dezawa MUSEcells™: Understanding Dose, Value, and When Each Makes Sense If you've been looking into regenerative medicine, you've probably run into two terms a lot. Mesenchymal stem cells, or MSCs, and Dezawa MUSEcells. Your first question is probably the obvious one. Which one should I actually get? At STEMS Health, Drs. Ankeet Choxi and Jarred Mait get this question constantly. The honest answer is, it depends on your biology, your condition, and the dose required to get the job done. MSCs work through paracrine signaling. They release bioactive molecules that calm inflammation and support tissue repair across a broad area. They're not precise, but they're powerful when you need a wide, systemic effect. Dezawa MUSEcells are different. They're a distinct pluripotent cell population discovered by Dr. Mari Dezawa, and their defining trait is precision. They self-direct toward damaged tissue, responding to the body's own distress signals, and differentiate once they get there. Think of MSCs as a wide net, and MUSEcells as cells that already know where they're going. Here's where patients are usually surprised. A typical MSC protocol might use around fifty million cells. A Dezawa MUSEcells protocol often uses somewhere between ten and twenty five million. That's not because MUSEcells are a lesser therapy. It's because they work differently. Since they home directly to the site that needs them, you need fewer cells to get a comparable, or even better, result. That's also where the value conversation comes in. As an MSC dose climbs higher, the cost climbs with it. At a certain point, a much smaller dose of Dezawa MUSEcells becomes more efficient and more cost effective. That's not a sales discount. It's just what happens when you need far fewer cells to do the same work. That said, MUSEcells aren't automatically the better choice for everyone. Some conditions call for the broad effect a higher volume MSC protocol provides. Others are better served by the targeted, lower dose approach. So how do you know which one is right for you? That comes down to a structured evaluation, looking at your inflammatory baseline, your imaging at the treatment site, and your prior treatment history. That evaluation, not a default package, determines whether MSCs, Dezawa MUSEcells, or a specific dose of either, is the right fit. One more thing worth mentioning. Exosomes, tiny vesicles released by MSCs, are still part of the toolkit and may come up in your evaluation. But for most patients today, the real decision point is MSCs versus MUSEcells, with dose as the key variable. If you're trying to figure out where you fall in that comparison, the next step is a real evaluation with Drs. Choxi and Mait, not a guess based on a podcast. Reach out to STEMS Health to find out which path fits your biology. Disclaimer The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs. Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration. Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment. © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
#46
June 28 · 5 min
Ep. 41 Does More Dezawa Muse Stem Cells Mean Better Results?
To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- Does More Dezawa Muse Stem Cells Mean Better Results? In regenerative medicine, numbers move people. Cell counts appear in marketing materials, comparison charts, and patient forums. The assumption behind them is intuitive: more cells delivered to a damaged tissue should mean a stronger regenerative signal, a faster recovery, a better outcome. At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait encounter this assumption constantly. And their clinical experience points to a different conclusion. Cell count is a data point. It is not a clinical outcome. What determines whether a Dezawa Muse stem cell preparation actually performs is not how many cells are in the vial. It is whether those cells are potent, whether they are viable, and whether they are being administered with physician-guided precision to a correctly identified target. Potency refers to a cell's functional capacity. Can it recognize and home to damaged tissue? Can it differentiate into the appropriate cell type once it arrives? Can it modulate the immune environment in a way that supports healing rather than triggering resistance? These are biological capabilities — not quantities. A preparation with a lower cell count but high potency, confirmed through strong SSEA-3 expression and robust differentiation markers, will outperform a high-volume, low-potency preparation in virtually every clinical scenario. Viability refers to how many of those cells are alive and metabolically active at the moment of injection. Cells lose viability during handling, transport, and storage. A preparation marketed at a high cell count may arrive at the injection site with a fraction of those cells actually capable of therapeutic activity. Dead cells produce no regenerative signal. They do not differentiate. They do not modulate. They simply occupy space in a protocol that the patient paid for and trusted. This is why the sourcing environment, processing standards, and delivery timing of a Muse cell preparation carry clinical weight. At STEMS Health, lab data on each preparation is reviewed before administration. Viability percentage, SSEA-3 positivity, differentiation capacity — these are not background details. They are part of the clinical decision. There is also a risk that runs counter to the more-is-better assumption. Introducing an excessive volume of biological material into the body without calibration to the patient's immune status, inflammatory baseline, and injury profile can trigger unintended inflammatory cascades. The goal of a regenerative protocol is not to maximize cell volume. It is to deliver cells that are fit to perform, in a quantity appropriate to the patient's individual biology, at a site that has been confirmed through diagnostic precision. At STEMS Health, every Muse cell protocol begins with a structured pre-treatment evaluation. The diagnosis is confirmed through imaging and clinical correlation. The patient's immune and inflammatory baseline is assessed. The preparation is reviewed for quality markers. The injection site is evaluated for anatomical targeting. Only when that evaluation is complete does the protocol take shape. That process cannot be replaced by a higher number on a marketing sheet. It requires a physician who understands what they are treating, why they are treating it, and what quality of biological material is being delivered into a body that is depending on that judgment. When patients evaluate regenerative medicine providers, the most important questions are not about volume. They are about potency, viability, diagnostic process, and physician-guided protocol design. Those are the variables that determine what happens after treatment. And at STEMS Health, those are the variables that guide every decision made before it. This is STEMS Health — regenerative medicine in Miami Beach, guided by clinical precision.

Showing 1–20 of 25 episodes